Hem › Myelofibros › Kansas
Kliniska studier för Myelofibros i Kansas
6 studier för Myelofibros söker deltagare vid platser i Kansas.
Officiell studietext (engelska)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- och 1 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT06661915A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Kansas Medical Center, Kansas City
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT06343805Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
- The University of Kansas Cancer Center, Fairway
RekryterarTidig fas 1Friska volontärer välkomna
Ålder 18 och äldre · Alla kön · Uppdaterad 6 maj 2026 · NCT06414681A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- The University of Kansas Cancer Center, Westwood
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 17 apr. 2026 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
RekryterarFas 2
Ålder 18 till 66 · Alla kön · Uppdaterad 17 mars 2026 · NCT06859424Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- University of Kansas Cancer Center - Westwood, Westwood
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2025 · NCT06479135Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.